This is a working overview of lyophilised powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-03. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Neptunium nitride (NpN) was first prepared in 1953 by reacting neptunium hydride and ammonia gas at around 750 °C in a quartz capillary tube. Later, it was produced by reacting different mixtures of nitrogen and hydrogen with neptunium metal at various temperatures. It has also been produced by the reduction of neptunium dioxide with diatomic nitrogen gas at 1550 °C. NpN is isomorphous with uranium mononitride (UN) and plutonium mononitride (PuN) and has a melting point of 2830 °C under a nitrogen pressure of around 1 MPa. Two neptunium phosphide compounds have been reported, NpP and Np3P4. The first has a face centered cubic structure and is prepared by converting neptunium metal to a powder and then reacting it with phosphine gas at 350 °C. Np3P4 can be produced by reacting neptunium metal with red phosphorus at 740 °C in a vacuum and then allowing any extra phosphorus to sublimate away. The compound is non-reactive with water but will react with nitric acid to produce Np(IV) solution. Three neptunium arsenide compounds have been prepared, NpAs, NpAs2, and Np3As4. The first two were first produced by heating arsenic and neptunium hydride in a vacuum-sealed tube for about a week. Later, NpAs was also made by confining neptunium metal and arsenic in a vacuum tube, separating them with a quartz membrane, and heating them to just below neptunium's melting point of 639 °C, which is slightly higher than the arsenic's sublimation point of 615 °C. Np3As4 is prepared by a similar procedure using iodine as a transporting agent. NpAs2 crystals are brownish gold and Np3As4 is black.
The majority of I-131 will be eliminated from the human body in 3–5 days, through natural decay, and through excretion in sweat and urine. Smaller amounts will continue to be released over the next several weeks, as the body processes thyroid hormones created with the I-131. For this reason, it is advised to regularly clean toilets, sinks, bed sheets and clothing used by the person who received the treatment. Patients may also be advised to wear slippers or socks at all times, and avoid prolonged close contact with others. This minimizes accidental exposure by family members, especially children. Use of a decontaminant specially made for radioactive iodine removal may be advised. The use of chlorine bleach solutions, or cleaners that contain chlorine bleach for cleanup, are not advised, since radioactive elemental iodine gas may be released. Airborne I-131 may cause a greater risk of second-hand exposure, spreading contamination over a wide area. Patient is advised if possible to stay in a room with a bathroom connected to it to limit unintended exposure to family members. Many airports have radiation detectors to detect the smuggling of radioactive materials. Patients should be warned that if they travel by air, they may trigger radiation detectors at airports up to 95 days after their treatment with 131I.
== Decision-making == Under Article 11.(c) of the Draft Constitutional Declaration, the Sovereignty Council makes decisions either by consensus, or when consensus is not possible, by a two-thirds majority (eight members).
=== Frequency multiplier === In 2009, researchers built experimental graphene frequency multipliers that take an incoming signal of a certain frequency and output a signal at a multiple of that frequency.
Sources: en.wikipedia.org
=== Social costs === Dementia, and specifically Alzheimer's disease, may be among the most costly diseases for societies worldwide. As populations age, these costs will probably increase and become an important social problem and economic burden. Costs associated with AD include direct and indirect medical costs, which vary between countries depending on social care for a person with AD. Direct costs include doctor visits, hospital care, medical treatments, nursing home care, specialised equipment, and household expenses. Indirect costs include the cost of informal care and the loss in productivity of informal caregivers. In the United States as of 2019, informal (family) care is estimated to constitute nearly three-fourths of caregiving for people with AD at a cost of US$234 billion per year and approximately 18.5 billion hours of care. The cost to society worldwide to care for individuals with AD is projected to increase nearly ten-fold, and reach about US$9.1 trillion by 2050. Costs for those with more severe dementia or behavioral disturbances are higher and are related to the additional caregiving time to provide physical care.
== Pathogenicity mechanisms and virulence factors == Burkholderia pseudomallei is an opportunistic pathogen and, since its an environmental organism, has no requirement to pass through an animal host to replicate. From the point of view of the bacterium, human infection is a developmental "dead end". Strains which cause disease in humans differ from those causing disease in other animals, by possessing certain genomic islands. It may have the ability to cause disease in humans via DNA acquired from other microorganisms. Its mutation rate is also high, and the organism continues to evolve even after infecting a host. Burkholderia pseudomallei is able to invade cells - being an intracellular pathogen. It is able to polymerise actin, and to spread from cell to cell, causing cell fusion and the formation of multinucleated giant cells. It possesses a uniquely fusogenic type VI secretion system that is required for cell-cell spread and virulence in mammalian hosts. The bacterium also expresses a toxin called lethal factor 1. B. pseudomallei is one of the first Proteobacteria to be identified as containing an active type VI secretion system. It is also the only organism identified that contains up to six different type VI secretion systems. B. pseudomallei is intrinsically resistant to many antimicrobial agents by virtue of its efflux pump mechanism. This mediates resistance to aminoglycosides (AmrAB-OprA), tetracyclines, fluoroquinolones, and macrolides (BpeAB-OprB).
== Rugby league scandals == Melbourne Storm salary cap breach – in 2010, the Melbourne Storm were punished for breaching the salary cap and were stripped of the ability to accumulate points, had their name stripped from the premierships and minor premierships they had gained over the previous four years and forced to pay back millions of dollars of prize money. It is the toughest punishment for a salary cap breach in NRL history. Cronulla Sharks supplements doping scandal – following an extensive investigation by ASADA, players from the Cronulla Sharks were found guilty of having used the banned peptide CJC-1295, resulting in the suspensions of fourteen players. A number of senior staff were dismissed or resigned and several senior club members received penalties and suspensions. Matthew Johns sexual assault allegations – in 2002, while on a trip to New Zealand, Cronulla-Sutherland Sharks player Matthew Johns took part in degrading group sex with a young woman while up to 11 of his teammates joined in. The scandal was reported by the ABC's Four Corners TV series. Johns admitted having consensual sex with the girl and made a public apology on Channel Nine's The Footy Show. Johns was suspended from The Footy Show and was released by the Melbourne Storm as their assistant coach.
In 2016, the breakdown of a 20-year truce between the PCC and the Red Command (CV) led to a massive uptick in violence across Brazil, with the PCC embarking on an aggressive expansion campaign by absorbing less organized gangs and financing local groups to operate as proxies against the CV across the country, such as the B13 gang in Acre and the CV's rivals in Rio de Janeiro. Between 2016 and 2020, a series of gruesome prison riots made headlines worldwide as the PCC fought for control of the North Region against the Família do Norte, allies with the Comando Vermelho. On January 1, dozens of PCC prisoners were massacred at the Anísio Jobim Penitentiary Complex in Manaus after a prison riot, with the PCC retaliating in prison riots in Boa Vista and in Natal in the same week. Dismemberments, beheadings and prisoners being burned alive were commonplace during all three prison riots. Between 2015 and 2018, the Familia do Norte and the Comando Vermelho (CV) formed an alliance to prevent the advance of the Primeiro Comando da Capital (PCC) in Amazonas. In 2018, the alliance dissolved, generating a confrontation between the CV and Familia do Norte, weakening the faction. 33 prisoners were killed in the Agricultural Penitentiary of Monte Cristo riot, located in the rural area of Boa Vista, Roraima, also in the North. According to Folha de S.Paulo, the massacre in Roraima was a response of the PCC to the rebellion commanded by the FDN in the Amazon. Even more people were killed later on in the month. More than 106 were the fatalities during those prison riots.
=== Environmental Engineering === Water desalination (e.g. new membranes for highly-efficient low-cost ion removal) Soil remediation (e.g. catalytic nanoparticles that accelerate the degradation of long-lived soil contaminants such as chlorinated organic compounds) Carbon sequestration (e.g. new materials for CO2 adsorption)
Sources: en.wikipedia.org
==== Coloration ==== Mammalian coats are colored for a variety of reasons, the major selective pressures including camouflage, sexual selection, communication, and thermoregulation. Coloration in both the hair and skin of mammals is mainly determined by the type and amount of melanin; eumelanins for brown and black colors and pheomelanin for a range of yellowish to reddish colors, giving mammals an earth tone. Some mammals have more vibrant colors; certain monkeys such mandrills and vervet monkeys, and opossums such as the Mexican mouse opossums and Derby's woolly opossums, have blue skin due to light diffraction in collagen fibers. Many sloths appear green because their fur hosts green algae; this may be a symbiotic relation that affords camouflage to the sloths. Camouflage is a powerful influence in a large number of mammals, as it helps to conceal individuals from predators or prey. In arctic and subarctic mammals such as the arctic fox (Alopex lagopus), collared lemming (Dicrostonyx groenlandicus), stoat (Mustela erminea), and snowshoe hare (Lepus americanus), seasonal color change between brown in summer and white in winter is driven largely by camouflage. Some arboreal mammals, notably primates and marsupials, have shades of violet, green, or blue skin on parts of their bodies, indicating some distinct advantage in their largely arboreal habitat due to convergent evolution.
== History == Viscofan was founded in 1975, which is also when it began producing and selling its products. In 1988, Viscofan acquired the food group IAN (Industrias Alimentarias de Navarra), aiming to improve its presence in the Spanish market. Viscofan continued its international expansion by acquiring the German company Naturin GmbH & Co. in 1990 and opening new commercial offices overseas. Additional acquisitions included Gamex in the Czech Republic (1995), Trificel in São Paulo, Brazil (1995), Koteksprodukt AD in Serbia (2005), and the assets of Sweden's AB Tripasin (2005). In 2006, Viscofan broadened its footprint in the Americas by acquiring the U.S. and Mexican assets of Teepak. In 2008, Viscofan expanded its cogeneration plant in Spain. That same year, the company launched Viscofan Bioengineering, a business unit that merges bioscience and engineering to develop collagen-based products intended for tissue repair. The Bioengineering unit is located in Weinheim (Germany), where Viscofan also maintains a production site for collagen casings and an additional cleanroom facility for manufacturing medical-grade collagen materials. In 2009, Viscofan established Viscofan Technology (Suzhou) Co. Ltd. in China. The following year, it opened a converting plant in the country. In 2012, the company created Viscofan Uruguay S.A., followed by the opening of a collagen extrusion plant in China in 2013 and another extrusion facility in Uruguay in 2014. In 2015, Viscofan sold the IAN Group to focus on its casings business.
Lead coolant temperature would be around 540 °C, giving a high efficiency of 43%, primary heat production of 700 MWt yielding electrical power of 300 MWe. The operational lifespan of the unit could be 60 years. The design was expected to be completed by NIKIET in 2014 for construction between 2016 and 2020. In January 2026, Rosatom reported that BREST-OD-300 remained under construction and that the metal shell of its central reactor cavity had been installed during 2025.
=== Competition === There are currently two products approved as maintenance therapy following treatment of inoperable locoregional Stage III NSCLC with induction chemotherapy: Tarceva (erlotinib), a targeted small molecule from Genentech, a member of the Roche Group, and Alimta (pemetrexed), a chemotherapeutic from Eli Lilly and Company. Tecemotide has not been tested in combination with or in comparison to these products. It is possible that other existing or new agents will be approved for this indication. In addition, there are at least two vaccines in development for the treatment of NSCLC, including GSK's MAGE A3 vaccine in Phase 3 and Transgene's TG-4010 in Phase 2/3. TG-4010 also targets MUC1, although using technology different from tecemotide.
). Thus, the number of free parameters in the NCM model always exceeds the number of homologous characters in the data matrix, and the NCM model has been criticized as consistently "over-parameterized."
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.